The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of conversion therapy for esophageal squamous cell carcinoma.
 
Takayuki Tsuji
No Relationships to Disclose
 
Hirofumi Kawakubo
No Relationships to Disclose
 
Masashi Takeuchi
No Relationships to Disclose
 
Satoru Matsuda
No Relationships to Disclose
 
Kazumasa Fukuda
No Relationships to Disclose
 
Rieko Nakamura
No Relationships to Disclose
 
Yuko Kitagawa
Honoraria - Asahi Kasei; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Pharma; Ethicon; Kaken Pharmaceutical; MSD K.K.; Nippon Covidien; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Smith & Nephew; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb K.K.; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Medicon (Inst); Nihon Pharma (Inst); Nippon Covidien (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst); Yakult Honsha (Inst)